Fludarabine, busulfan, and melphalan conditioning regimen in allogeneic hematopoietic stem cell transplantation for adult patients with myeloid malignancies: A multicenter retrospective study

Autor: Jieling Jiang, Xiaofan Li, Dong Wu, Quanyi Lu, Kourong Miao, Houcai Wang, Xiaoping Li, Yingnian Chen, Shiyuan Zhou, Yali Zhou, Guiping Liao, Chuanhe Jiang, Xiaohong Yuan, Youshan Zhao, Chunkang Chang, Jie Chen, Han Zhu, Ruye Ma, Nainong Li, Xiaolin Yin, Xiaojin Wu, Sanbin Wang, Chun Wang, Jiong Hu

Publikováno v: eJHaem, Vol 5, Iss 4, Pp 757-767 (2024)

Abstract Relapse remains the main cause of treatment failure in patients with myeloid malignancies even after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We observed a particularly low incidence of relapse in patients prepared w

Externí odkaz: https://doaj.org/article/94ac479f3e48422e8c85d2f38c9f67db

CD7 targeted 'off-the-shelf' CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T-cell malignancies

Autor: Shiqi Li, Xinxin Wang, Le Luo, Jia Liu, Jun Rao, Lin Liu, Li Gao, Zhongtao Yuan, Yu Li, Gui Li, Duanpeng Wang, Sheng Li, Jiaping He, Lihua Zhang, Lvzhe Chen, Ping Yin, Chunmin Li, Xiaoping Li, Youcheng Wang, Yancheng Dong, Dingsong Zhang, Lihua Fang, Yingnian Chen, Lianjun Shen, Wenling Li, Wei Cao, Xi Zhang, Sanbin Wang

T-cell acute lymphoblastic leukemia (T-ALL) represents an area of high unmet medical needs. Once relapsed, patients have limited treatment options and usually a poor prognosis. T-ALL antigens such as CD7 is extensively expressed in normal T cells and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c74f7415b9928304f4f848f334e4d67
https://doi.org/10.21203/rs.3.rs-2431426/v1

Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management

Autor: Lihua Fang, Dingsong Zhang, Xinxin Wang, Duanpeng Wang, Le Luo, Jia Liu, Cong Han, Yu Li, Zhimin Li, Wei William Cao, Lianjun Shen, Chunhui Yang, Jiaping He, Xun Ye, Lin Liu, Martina Sersch, Shiqi Li, Yingnian Chen, Sanbin Wang, Zhongtao Yuan, Yancheng Dong, Kun Wu, Youcheng Wang

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 27(5)

Purpose: Although chimeric antigen receptor T-cell (CAR-T) therapy development for B-cell malignancies has made significant progress in the last decade, broadening the success to treating T-cell acute lymphoblastic leukemia (T-ALL) has been limited.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f92446754b751a582ea53b3a41c204
https://pubmed.ncbi.nlm.nih.gov/33234511

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T.

Autor: Shiqi L; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Jiasi Z; Center for Hematology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, China., Lvzhe C; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Huailong X; Chongqing Precision Biotech Co., Ltd., Chongqing 400039, China., Liping H; Department of Epidemiology and Health Statistics, School of Public Health, Kunming Medical University, Kunming, Yunnan 650500, China., Lin L; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Qianzhen Z; Chongqing Precision Biotech Co., Ltd., Chongqing 400039, China., Zhongtao Y; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Junjie S; Chongqing Precision Biotech Co., Ltd., Chongqing 400039, China., Zucong C; The People's Hospital of Dehong Prefecture, Dehong, Yunnan Province 678400, China., Yingzi Z; Chongqing Precision Biotech Co., Ltd., Chongqing 400039, China., Meiling W; Chongqing Precision Biotech Co., Ltd., Chongqing 400039, China., Yunyan L; Chongqing Precision Biotech Co., Ltd., Chongqing 400039, China., Linling W; Chongqing Precision Biotech Co., Ltd., Chongqing 400039, China., Lihua F; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Yingnian C; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Wei Z; Chongqing Precision Biotech Co., Ltd., Chongqing 400039, China., Yu L; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Le L; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Youcheng W; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Dingsong Z; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Yancheng D; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Ping Y; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Lihua Z; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Xiaoping L; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China., Xiaozhuang H; Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai 201318, China., Zhongzheng Z; Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai 201318, China., Zhi Y; Chongqing Precision Biotech Co., Ltd., Chongqing 400039, China., Cheng Q; Chongqing Precision Biotech Co., Ltd., Chongqing 400039, China., Sanbin W; Department of Hematology, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan Province 650100, China.

Publikováno v: Molecular therapy oncolytics [Mol Ther Oncolytics] 2023 Apr 20; Vol. 29, pp. 107-117. Date of Electronic Publication: 2023 Apr 20 (Print Publication: 2023).